Abstract:OBJECTIVE:To investigate the apoptosis and Fas (CD95) expression of T lymphocytes from the peripheral blood and peritoneal fluid of the patients with ovarian cancer and their relationship with CA125. METHODS:Apoptosis and Fas expression of peritoneal fluid and peripheral blood T lymphocytes were assessed by flow cytometry. Peripheral blood samples were obtained from the following objects respectively: patients with stage III - IV ovarian cancer (n = 18) before and after treatment, patients with stage I - II ovarian cancer (n = 15), patients with benign ovarian tumor (n = 18), patients with Krukenberg tumor (n = 6) and normal control (n = 20). Peritoneal fluids were obtained from all the patients with ovarian cancer, Krukenberg tumor and ten patients with benign ovarian tumor. Level of serum CA125 of the patients with ovarian cancer was assessed. RESULTS:In the patients with stage III - IV ovarian cancer, the apoptosis level of the peripheral blood T lymphocytes was 5.55 (3.57 - 9.62)%, significantly higher than those from the patients with stage I - II ovarian cancer, patients with benign ovarian tumor, controls (P < 0.008 in all instances) and the patients with stage III - IV ovarian cancer after treatment (P < 0.05). The intensity of Fas expression of the peripheral blood T lymphocytes from the patients with stage III - IV ovarian cancer was 51 +/- 10, significantly higher than that from controls (P < 0.05). In peritoneal fluid, the apoptosis rates of T lymphocytes, positive rate and intensity of Fas expression on T lymphocytes from patients with stage I - II and stage III - IV ovarian cancer were 17.41 (7.06 - 24.56)%, (57 +/- 16)%, (55 +/- 11)% and 34.06 (17.03 - 44.65)%, (66 +/- 12)%, (70 +/- 24)%, respectively, increased significantly compared with those from patients with benign ovarian tumor, which were 0.78 (0.67 - 1.44)%, (37 +/- 6)%, 43 +/- 6, respectively (P < 0.01 in all instances). The apoptosis level and positive rate of Fas expression on peritoneal fluid T lymphocytes from patients with stage III - IV ovarian cancer were significantly higher than those from patients with Krukenberg tumor (P < 0.01). There was a positive correlation between the serum CA125 level and the apoptosis level of peritoneal fluid T cell in the patients with stage I - II ovarian cancer (r = 0.77, P = 0.009). For ovarian cancer, the apoptosis level of peritoneal fluid T lymphocytes from patients with the serum CA125 > 500 KU/L was higher than that from the patients with the serum CA125 < or = 500 KU/L (P = 0.009). CONCLUSIONS:(1) Extraordinarily increased apoptosis of T cells may play an important role in the development of systemic and celiac immunodeficiency in the patients with ovarian cancer. In contrast with the patients with Krukenberg tumor, the patients with advanced ovarian cancer hare higher percentage of apoptotic peritoneal fluid T lymphocytes, which shows the particularity of local immunity defect. (2) For the patients with ovarian cancer, efficient treatment can decrease the percentage of apoptotic peripheral blood T lymphocytes. (3) The increased positive rate and intensity of Fas expression on peritoneal fluid T lymphocytes stressed the significance of Fas interference in the treatment of ovarian cancer. (4) Level of serum CA125 can reflect the celiac immunity defection in patients with ovarian cancer.

Fas and FasL expressions on the different stages of large intestine malignant transformation and their significance in apoptosis escape of cancer

Fas Ligand Expression in Colon Cancer: A Possible Mechanism of Tumor Immune Privilege

FasL Expression in Human Colon Carcinomas

Loss of Fas Expression and High Expression of HLA-E Promoting the Immune Escape of Early Colorectal Cancer Cells.

[Expression of Fas, Fas Ligand, Fas-associated Death Domain Protein, Caspase 8 and Mutant P53 Protein in Esophageal Squamous Cell Carcinoma].

Considering Fas ligand as a target for therapy.

Fas-mediated Pathway and Apoptosis in Normal Cervix, Cervical Intraepithelial Neoplasia and Cervical Squamous Cancer.

Suppression of Tumor Cell Immune Counterattack by Blocking FasL Expression in Pancreatic Cancer Cells

Fas ligand and tumour counter-attack in colorectal cancer stratified according to microsatellite instability status

Expression of FLIP in Human Colon Carcinomas: A New Mechanism of Immune Evasion

[The influence of FasL gene expression upon hepatic metastasis of colorectal carcinoma]

Influence of FasL gene expression on hepatic metastasis of colorectal carcinoma

Study of Apoptosis and Fas Expression of Peritoneal Fluid and Peripheral Blood T Lymphocytes in Patients with Epithelial Ovarian Cancer and Their Relationship with CA125

Study Progress of Fas/Fas L and Survivin in Breast Cancer

Expression and Significance of Fatty Acid Synthase in Rectal Aberrant Crypt Foci in Patients with Colon Cancer

Activated Cytotoxic Lymphocytes Promote Tumor Progression by Increasing the Ability of 3LL Tumor Cells to Mediate MDSC Chemoattraction Via Fas Signaling.

The Fas Expression in Gastric Cancer Cells and Peripheral Lymphocytes

The Expression of Fas,FasL in Laryngeal Carcinoma and Its Clinical Significance

Blockade of Fas Signaling in Breast Cancer Cells Suppresses Tumor Growth and Metastasis Via Disruption of Fas Signaling-initiated Cancer-related Inflammation*

Apoptosis Induced by Preoperative Oral 5’-DFUR Administration in Gastric Adenocarcinoma and Its Mechanism of Action

Fas/FasL and survivin expression in colorectal cancer cells after preoperative chemotherapy